News Archives

October 14, 2015 BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos
October 5, 2015 Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study
October 5, 2015 Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)
October 1, 2015 Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society
September 30, 2015 Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol
September 30, 2015 FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015
September 25, 2015 WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions
September 24, 2015 Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform
September 24, 2015 BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors
September 21, 2015 Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer